(SWTX) SpringWorks Therapeutics - Ratings and Ratios

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for underserved patient populations with rare diseases and cancer. The company’s lead products include OGSIVEO (nirogacestat), a gamma secretase inhibitor approved for desmoid tumors, and GOMEKLI (mirdametinib), an MEK inhibitor for NF1-associated plexiform neurofibromas. Its pipeline also includes nirogacestat in Phase 2 for ovarian granulosa cell tumors and mirdametinib in Phase 1/2 for pediatric low-grade gliomas. The company is also developing Brimarafenib, a BRAF inhibitor, and has a portfolio of TEA Domain inhibitors licensed from academic institutions. SpringWorks leverages partnerships, including with Pfizer, to advance its therapies.

From a technical perspective, SWTX is trading above its 20-day SMA of 40.04 but below its 50-day SMA of 47.18. The stock’s ATR of 2.74 reflects moderate volatility. The 3-month forecast suggests potential resistance near the 50-day SMA, with a possible breakout above 47.18 signaling upward momentum. Conversely, failure to breach this level may lead to range-bound trading between 40.04 and 47.18.

Fundamentally, SpringWorks has a market cap of $2.84 billion, with a forward P/E of 322.58, reflecting high expectations for future earnings despite current losses. The P/S ratio of 14.84 indicates a premium valuation relative to sales. With an RoE of -53.65, the company is operating at a net loss, which is common for early-stage biotech firms. Investors are likely pricing in the potential for future growth driven by its pipeline and commercial assets.